novel platforms based on DNA or mRNA offer great flexibility in terms of antigen manipulation and potential for speed. Indeed, Moderna started clinical testing of its mRNA-based vaccine mRNA-1273 just 2 months after sequence identification. Vaccines based on viral vectors offer a high level of protein expression and long-term stability, and induce strong immune responses. Finally, there are already licensed vaccines based on recombinant proteins for other diseases, and so such candidates could take advantage of existing large-scale production capacity.
Interesting COVID-19 vaccine development landscape publication in Nature.
Here’s a snippet from it...
It also links to WHO’s spreadsheet of COVID-19 candidate vaccines, which looks like a good resource in its own right (although this particular copy is probably a bit old).
A nice graphical guide on COVID-19 vaccines: https://www.nature.com/articles/d41586-020-01221-y